<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35321">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646748</url>
  </required_header>
  <id_info>
    <org_study_id>39110-107</org_study_id>
    <nct_id>NCT02646748</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors</brief_title>
  <official_title>A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 1b, 3 Part (Part 1a, Part 1b and Part 2), multi-center study.

      Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced
      solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib
      (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a
      PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum
      tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each
      combination.

      Once the recommended dose has been identified in Part 1a, subjects with select solid tumor
      types will be enrolled into safety expansion cohorts based upon prior treatment history with
      a PD-1 pathway-targeted agent (Part 1b) for each combination.

      Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with
      pembrolizumab in patients with small cell lung cancer (SCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1b, 3 Part (Part 1a, Part 1b, and Part 2), multi-center study.

      Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced
      solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib
      (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a
      PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum
      tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each
      combination.

      Once the recommended dose has been identified in Part 1a, subjects with endometrial cancer,
      gastric cancer, melanoma, microsatellite unstable (MSI) colorectal cancer or other
      MMR-deficient tumors, non-small cell lung cancer, renal cell carcinoma, head and neck
      squamous cell carcinoma, triple negative breast cancer, pancreatic ductal carcinoma, or
      transitional cell carcinoma of the genitourinary tract will be enrolled into safety
      expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent
      (Part 1b) for each combination.

      Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with
      pembrolizumab in patients with small cell lung cancer (SCLC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events</measure>
    <time_frame>Duration of study treatment and up to 120 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as determined by radiographic disease assessments per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 criteria</measure>
    <time_frame>Every 9 weeks for the first year on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as measured by the duration from the date of first dose until the earliest date of disease progression or death as measured by immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1</measure>
    <time_frame>Every 9 weeks for the first year on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as measured from the time of the earliest response complete response (CR) or partial response (PR) until disease progression per irRECIST v1.1</measure>
    <time_frame>Every 9 weeks for the first year on study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Microsatellite Unstable (MSI) Colorectal Cancer</condition>
  <condition>MMR-deficient Tumors</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Transitional Cell Carcinoma of the Genitourinary Tract</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pembrolizumab + itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab + INCB050465</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.
Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be an intravenous (IV) infusion, day 1 of every 3 week cycle.</description>
    <arm_group_label>pembrolizumab + itacitinib</arm_group_label>
    <arm_group_label>pembrolizumab + INCB050465</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itacitinib</intervention_name>
    <description>itacitinib tablets will be administered orally once daily.</description>
    <arm_group_label>pembrolizumab + itacitinib</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>INCB050465 tablets will be administered orally once daily.</description>
    <arm_group_label>pembrolizumab + INCB050465</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 18 years or older.

          -  Willingness to provide written informed consent for the study.

          -  Has baseline tumor biopsy specimen available or willingness to undergo a pretreatment
             tumor biopsy to obtain the specimen.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          -  For Part 1a: Subjects with histologically or cytologically confirmed advanced or
             metastatic solid tumors that have failed prior standard therapy (including subject
             refusal or intolerance).

          -  For Part 1b: Subjects with histologically or cytologically confirmed advanced or
             metastatic endometrial cancer, gastric cancer, melanoma, microsatellite unstable
             (MSI) colorectal cancer or other MMR-deficient tumors, non-small cell lung cancer,
             renal cell carcinoma, head and neck squamous cell carcinoma, triple negative breast
             cancer, pancreatic ductal carcinoma, or transitional cell carcinoma of the
             genitourinary tract that have had disease progression after available therapies for
             advanced or metastatic disease that are known to confer clinical benefit, been
             intolerant to treatment, or refused standard treatment.

          -  For Part 1b: Must have documented confirmed disease progression on a prior PD-1
             pathway targeted agent or must be PD-1 pathway-targeted treatment na√Øve.

          -  For Part 2: Subjects with histologically or cytologically confirmed advanced or
             metastatic SCLC. Must not have had previous treatment with antibodies that modulate
             T-cell function or checkpoint pathways. Must have disease progression on or after
             platinum-based chemotherapy or must be intolerant to or refuse standard treatment.
             Must not have received more than 2 lines of prior therapy.

        Exclusion Criteria:

          -  Laboratory parameters not within the protocol-defined range.

          -  Receipt of anticancer medications or investigational drugs within a defined interval
             before the first administration of study drug.

          -  Received an immune-suppressive based treatment for any reason within 14 days prior to
             the first dose of study treatment.

          -  Has not recovered from toxic effect of prior therapy to &lt; Grade 1.

          -  Active or inactive autoimmune process.

          -  Has received a live vaccine within 30 days of planned start of study therapy.

          -  Active infection requiring systemic therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Jones, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1.855.463.3463</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Port St. Lucie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 2, 2017</lastchanged_date>
  <firstreceived_date>January 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
